VERA
Vera Therapeutics Inc - Class A (VERA)
Healthcare • NASDAQ • $28.57+2.33%
- Symbol
- VERA
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $28.57
- Daily Change
- +2.33%
- Market Cap
- $2.01B
- Trailing P/E
- N/A
- Forward P/E
- -6.56
- 52W High
- $56.05
- 52W Low
- $23.05
- Analyst Target
- $74.20
- Dividend Yield
- 0.00%
- Beta
- 1.05
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections that has completed phase 2 clinical trial; and VT-109, a novel BAFF/APRIL dual-inhibitor B cell maturation antigen (BCMA) molecule to treat B cell mediated autoimmune diseases. The …
Company websiteResearch VERA on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.